EpiBiologics

📍 San Mateo, United States👥 49 employees💰 Last funded Jan 2026
Biotechnology Research🌐 epibiologics.com
Website LinkedIn
EpiBiologics is advancing bispecific antibodies that selectively degrade membrane and soluble proteins, including GPCRs. Our EpiTAC platform leverages a novel atlas of tissue-selective degrader receptors to drive deep and durable efficacy. The company was founded in 2022 based on pioneering work from Dr. Jim Wells at UCSF. Headquartered in the SF Bay Area, EpiBiologics is backed by leading healthcare investors and building a clinical stage pipeline for oncology and immunology. For more information, please visit epibiologics.com and follow us on LinkedIn.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United States
2
China
1
Investor activity2025–2026 · investors recorded per year
2025120262
Recent (last 2y)Earlier
Frequently asked questions
Who invested in EpiBiologics?
EpiBiologics has 3 investors on record on gritt.io.
When did EpiBiologics last raise funding?
The most recent investment in EpiBiologics recorded on gritt.io was in January 2026.
What industry is EpiBiologics in?
EpiBiologics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is EpiBiologics based?
EpiBiologics is headquartered in San Mateo, United States.